Ind-Swift Laboratories Ltd.

INDSWFTLAB

Market Cap
₹728 Cr.
P/E
16.45

Ind-Swift Laboratories Ltd.

Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics
Other Income
Other Income is not affecting ratios of the company
Pledge
Promoters have pledged a significant portion of their holding
Revenue Recognition
Company is converting accounting profit to cash
Depreciation Effect
Depreciation accounting is not leading to increase in profits
Capex vs ROCE
ROCE of the company has increased over the last three years
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been selling the stock which is usually a good time to buy
Share price
Share price has increased over last 10 years but more due to rerating
ROE
Net Profit Margin is responsible for ROE increase over last 10 years
Working Capital
Company has significant working capital which is dragging its ROCE and ROE
Debt
Company might have issues servicing its debt
Promoter Holding
Promoter has not sold any shares in the last 90 days
Current vs Historic Valuation
Company is trading at a discount to 3 year historic valuations
ROE
Latest
6.98%
3yr Average
2.03%
5yr Average
1.54%
Net Profit Margin
Latest
3.94%
3yr Average
1.13%
5yr Average
0.9%
ROCE
Latest
14.43%
3yr Average
10.09%
5yr Average
8.03%
Debt to Equity
Latest
1.25
3yr Average
1.49
5yr Average
1.6
Market Share
10% (as of Mar 20)
Atorvastatin (Digestive) - Market Share
locked Source
25% (as of Mar 20)
Clarithromycin (Respiratory) - Market Share
locked Source
15% (as of Mar 20)
Clopidogrel (Cardio) - Market Share
locked Source
8% (as of Mar 20)
Ezetimibe (Cardio) - Market Share
locked Source
20% (as of Mar 20)
Fexofenadine (Anti-Allergic) - Market Share
locked Source
25% (as of Mar 20)
Ivabradine (Cardio) - Market Share
locked Source
40% (as of Mar 20)
Nitazoxanide (Digestive) - Market Share
locked Source
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Operating Profit Break-Up

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • Total reactor capacity (kL)
      Source
    • DMF Filingsby API (.)
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline